🧬 当一种治疗在多个生物标志物定义的亚组中均有效时，其信息量不亚于发现一个“完美”的预测标志物。
@OncoAlert
在 #ESMO26 上，来自 III 期 evERA 乳腺癌研究的探索性 ctDNA 分析表明，giredestrant 联合 everolimus 在一系列生物学上具有挑战性的 CDK4/6i 后 ER+/HER2− 晚期 #BreastCancer 亚组中维持了 PFS 获益。
📊 在 365 例可评估 ctDNA 的患者中：
🔹 cTF ≥1%：PFS HR 0.52
🔹 cTF <1%：HR 0.61
🔹 ESR1 D538：HR 0.58
🔹 ESR1 Y537：HR 0.35
🔹 TP53 突变：HR 0.65
🔹 PIK3CA 突变：HR 0.55
🎯 这为何重要：尽管 ctDNA 负荷、ESR1 变异及不良预后分子特征存在差异，获益似乎依然持续。
对我来说，当前的关键问题是这些生物标志物主要是在告诉我们谁风险更高 —— 还是未来的分析能识别出谁从该策略中获得最大的绝对获益。
由 @stolaney1 及 evERA 研究者展示的优秀工作。
Pinging @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @kevinpunie @ElisaAgostinett
#OncoAlert #ESMO26 #BreastCancer #ESR1 #ctDNA #PrecisionOncology
243 浏览 · 4 赞 · 2 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 Retrospective Exploratory Biomarker Analyses From evERA Breast Cancer: A Phase III Trial of Giredestrant + Everolimus in Patients With Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Setting 🎙️ Sara Tolaney @stolaney1 🔬 Exploratory biomarker analysis of phase III evERA (365 ctDNA-evaluable): giredestrant + everolimus vs SOC endocrine therapy + everolimus in post-CDK4/6i ER+, HER2– aBC. ➡️ PFS HR 0.52 (0.39–0.70) with cTF ≥1%; 0.61 (0.40–0.94) with cTF <1% ➡️ ESR1m: PFS HR 0.58 (D538) and 0.35 (Y537) ➡️ TP53m PFS HR 0.65 (0.45–0.93); PIK3CAm 0.55 (0.36–0.83) ✅ Giredestrant + everolimus maintained greater PFS benefit regardless of cTF status, with benefit across all ESR1 variants and poor prognostic subgroups. #BreastCancer (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com